Pharmaceutical Technology7h
Central Nervous System Disorders by Neuroplast for Amyotrophic Lateral Sclerosis: Likelihood of Approval
Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.
Hosted on MSN4h
Herpes link to Alzheimer's opens doors for new treatments
Scientists from the University of Pittsburgh have discovered a surprising connection between Alzheimer's disease and the ...
‘Rally 4 Nally’ hosts its 4th annual polar plunge, closes in on $400K in donations
The 4th annual Rally 4 Nally polar plunge took place on Saturday to raise awareness and donations for ALS. Rally 4 Nally, is ...
The Financial8h
About 7% of US children and adolescents ages 6 to 19 have high total cholesterol
High levels of cholesterol are a risk factor for atherosclerosis and cardiovascular diseases, which can lead to ...
Pharmaceutical Technology7h
Anhydrous enol oxaloacetate by MetVital for Fatigue: Likelihood of Approval
Anhydrous enol oxaloacetate is under clinical development by MetVital and currently in Phase II for Fatigue. According to GlobalData, Phase II drugs for Fatigue does not have sufficient historical ...
Sandra Bullock makes rare public appearance at star-studded Lakers vs. Pistons game
The “Miss Congeniality” actress watched the Detroit Pistons defeat the Los Angeles Lakers 117-114 in a close game two days ...
Hold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline Dependency
J.P. Morgan analyst Tessa Romero has maintained their neutral stance on NMRA stock, giving a Hold rating yesterday.Don't Miss Our New Year's ...